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ABSTRACT
The NF- κB pathway has been demonstrated to be upregulated in supratentorial ependymoma
(ST-EPN). Whether the different NF- κB transcription factors contribute to ST-EPN tumorigenesis
however, has not been investigated. We assessed the degree to which NF- κB subunits p50 and RelA
interact with the ST-EPN fusion mutation C11orf95-RELA in regulating gene expression via
colocalization analysis in Hek293T cell nuclei. We analyzed the functional outcomes of overexpression of
p50 or RelA, or CRISPR/Cas9-mediated knockdown of p50, in combination with the C11orf95-RELA
fusion in vivo by examination of tumor area in P14 – 21 CD1 mice. We further analyzed the effects each
of these conditions have on transformed cell morphology using immunohistochemistry and microscopy.
Our results show that the C11orf95-RELA fusion and RelA more significantly colocalize with the
C11orf95-RELA fusion than does p50 in Hek293T cell nuclei. Overexpression of RelA in combination
with the C11orf95-RELA fusion generates larger tumors by P21, while CRISPR knockdown of p50 in
neural progenitor cells reduces tumor size, in comparison to age matched controls. While overexpression
of RelA with the WT C11orf95-RELA fusion generates tumors that recapitulate WT tumor morphology,
overexpression of p50 generates tumors with significantly altered transformed cell morphology. Our data
demonstrates that both NF- κB subunits RelA and p50 are capable of interacting with the oncogenic
C11orf95-RELA fusion, and that such interaction may contribute to ST-EPN tumorigenesis.
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INTRODUCTION
Categorization of Ependymoma
Brain tumors are the most common childhood solid malignancy, and because of remarkable advances
in treating many cancers outside of the brain, they have become the leading cause of cancer mortality in
children. Ependymomas are a class of primary neuroepithelial tumors of the central nervous system that
can arise along the entire neuroaxis including the ventricular system of the cerebral hemispheres, the
hindbrain, and the spinal cord (Pajtler et. Al. 2016). The neoplasms can be further subdivided into three
groups based upon their compartmental location and genetic features: posterior fossa, spinal cord, and
supratentorial. These malignancies can occur in both children and adults, although the occurrence of each
subtype differs based upon age group, and are overall more common in children than adults. According to
the 2014 report published by the Central Brain Tumor Registry of the United States (CBTRUS),
ependymomas account for approximately 10% of primary CNS tumors in children and adolescents ages 0
– 19 years, most of which arise in the posterior fossa. In contrast, ependymomas comprise about 5% of
adult CNS tumors, the majority of which arise in the spinal cord and posterior fossa region (Torre et. Al.
2019). There also appears to be a racial disparity in ependymoma incidence rate, with a rate of 0.40 per
100,000 incidences in white populations versus 0.27 in African Americans (Wu, Armstrong, and Gilbert,
2016).
The WHO classification of CNS tumors is currently accepted as the standard classification system,
and categorizes ependymomas as grade I, II, or III. Grade I ependymomas include slow-growing
ependymomas such as subependymomas and myxopapillary ependymomas. These are often slowgrowing and are typically considered benign neoplasms. On MRI scans, grade I ependymomas appear to
be sharply circumscribed and demarcated nodular masses. Grade II ependymomas are designated as
ependymoma. Multiple histological variants have been identified, including papillary, clear cell, cellular,
and tanycytic ependymomas. Nonpalisading geographic foci of necrosis are characteristic histological
features of Grade II ependymoma tumors. In contrast, Grade III tumors are designated as anaplastic
1

ependymomas. Pathognomonic histological features of these malignancies include perivascular
pseudorosettes, which originate from tumor cells arranged radially around blood vessels with a
perivascular anuclear zone, and true ependymal rosettes or tubules, which are ependymal cells arranged
around a central lumen. In comparison to the nonpalisading geographic foci of necrosis in Grade II
tumors, Grade III tumors present with pesudopalisading necrosis and microvascular proliferation.
Hypercellularity, vigorous mitotic activity, and hyperchomatic and pleomorphic nuclei are also frequently
observed in anaplastic ependymomas. Clinical manifestation of all grades are largely location dependent,
but may include chronic back pain and increased intracranial pressure (Godfraind C. 2009, Wu,
Armstrong, and Gilbert, 2016).
Identification of prognostic factors in ependymomas remains an important but controversial topic – in
part due to the difficulty in accurately diagnosing ependymomas. In a study of 2,408 ependymoma cases
from the Surveillance, Epidemiology and End Results (SEER) database between 1997 and 2005,
Rodriguez et. Al. identified the following factors to be associated with poor clinical outcome: younger
age, higher tumor grade, male sex, intracranial location, and failure to undergo extensive surgical
resection (Rodriguez et. Al. 2009). However, with growing data demonstrating histological, molecular,
and genetic differences between pediatric and adult ependymomas, prognostic factors may be different for
pediatric patients than those for adults and therefore must be analyzed separately. In a 2012 study from
the SEER database, Amirian et. Al. identified anaplastic histology and infratentorial tumor location to be
associated with increased mortality rate in pediatric patients, while supratentorial tumor location was
associated with higher mortality rate in adult patients (Amirian et. Al 2012).
To better account for variabilities in clinical feature information, sample number and study data
quality from different databases, the Collaborative Ependymoma Research Network (CERN) developed a
multi-institutional, clinically annotated tissue repository. This repository collected a wide variety of
information from each sample in an effort to better define clinical and demographic factors associated
with progression free survival (PFS) in adult ependymoma patients. Results indicated a significant
2

difference in PFS by tumor location. The median time to progression was only 3.9 years for the
supratentorial region, 12.3 years for the infratentorial brain region, and was not reached by patients with a
spinal cord location. In addition, patients younger than 44 years of age at the time of diagnosis had a
significantly shorter PFS than those older than 44 years of age. These results reaffirm those found in
earlier studies, and highlight a need for greater investigation of supratentorial ependymoma to reduce the
3.9 year PFS (Vera-Bolanos, Aldape, Yuan et. Al 2015). The CREN tissue repository was also utilized to
correlate individual histological features with clinical outcomes and specific ependymoma tumor biology.
Microvascular proliferation, elevated mitotic rates, and extensive ependymal canal formation were found
to be associated with a worse progression free survival in supratentorial tumors in comparison to posterior
fossa or spinal ependymomas. These histological features may serve as better measures of prognostic
importance than WHO grade in assessment of ependymoma subtypes, and suggest that the clinical
relevance of specific histological features in ependymomas appears to be related to the anatomical sites of
their origins.
In spite of these efforts to create histological criteria for categorizing ependymoma into risk groups,
extensive variability is seen in outcomes despite similarities in microscopic characteristics (Mangalore et.
Al. 2015). This suggests that ependymomas have discrete tumor biology that cannot be fully explained by
traditional histological classification. As a result, several molecular analyses have been undertaken to try
to elucidate the pathogenesis of ependymoma tumors in an effort to create better prognostic groupings
and potentially new therapeutic targets (Yao, Mack, and Taylor 2011; Pietsch et. Al. 2014; Parker et. Al.
2014; Wu, Albertson, and Gilbert 2016). The following will review the molecular genetic basis of
ependymoma – including familial genetic risk factors, early cytogenetic detections of chromosomal
abnormalities, and the identification of candidate driver events and pathways in ependymoma
tumorigenesis.
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Genetic Basis of Ependmoma
Like other cancers, ependymoma is a genetic disease. However, unlike many other cancers for which
existing familial cancer syndromes provide important clues for understanding tumorigenic mechanisms,
there are few known familial ependymoma syndromes. While there is increased incidence of spinal
ependymomas in patients with a loss of neurofibromatosis type 2 (NF2) on chromosome 22q, the NF2
gene does not appear to be the critical tumor suppressor gene on chromosome 22q that is involved in
intracranial ependymoma tumorigenesis (Yao, Mack, and Taylor 2011), Ependymoma has also been
reported in patients with germline mutations in the TP53 tumor suppressor gene. However, these
occurrences, as well as somatic mutations in TP53 in ependymomas are rare, thus weakening support for
the role of p53 in ependymoma tumorigenesis (von Haken MS, White EC, Daneshvar-Shyesther L, et. Al.
1996).
Over the years, cytogenetic studies using karyotyping and comparative genomic hybridization (CGH)
have reported numerous broad chromosomal abnormalities in ependymoma. Several studies over the last
two decades have also mounted building evidence supporting the notion that ependymomas are highly
heterogeneous tumors and can be classified into distinct disease subtypes based upon anatomical tumor
location, patient age, and genetic alterations. Combining such findings, cytogenetic abnormalities have
been further subdivided with distinct epednymoma disease subtypes. Commonly observed genomic
abnormalities in pediatric ependymomas include gains of chromosomes 1q, 5, 7, 8, 9, 11, 18, and 20, as
well as loss of chromosomes 1p, 2, 3, 6/6q, 9p, 13p, 17, and 22. In adult ependymomas, chromosomes 2,
5, 7, 9, 12, 18, and X are commonly gained whereas chromosomes 6, 10, 13q, 14q, 16, and 22/22q are
frequently lost (Kilday JP, Rahman R, Dyer S, et al. 2009). Location-specific genomic abnormalities are
roughly similar in children and adults in regards to intracranial versus spinal ependymomas. In addition to
genomic gains and losses, cytogenetic studies have also identified translocations occurring frequently
within the ependymoma genome. These often involve chromosomes 1, 11, and 22 (Mack and Taylor,
2008; de Bont, Packer, and Michiels et. Al. 2008; Aschero, Vallero, Morra et. Al. 2010).
4

Although the identified genomic gains and losses in ependymomas support findings for profile-based
stratification, they provide little insight into the tumor suppressors, oncogenes, and molecular pathways
responsible for the development of ependymoma. In addition, chromosome-level aberrations are broad
and typically span numerous genes, making it difficult to discriminate driver genetic events from indirect
passenger events. The use of array CGH (aCGH) in fine-mapping copy number variations in cancer, in
combination with analysis of gene expression levels, has expedited our understanding of potential
molecular genetic aberrations that may be driving ependymoma tumorigenesis. With advances in
microarray and next-generation sequencing technologies, examination of ependymoma genetics has
largely shifted towards detailed analysis of copy number variations and gene expression levels.
Genetic Aberrations in Supratentorial Ependymoma
While there have been several studies analyzing molecular genetic aberrations in posterior fossa and
spinal ependymomas, this review will focus on supratentorial ependymomas – the subject of this study. In
2010, Korshunov et. Al. identified homozygous deletion of the CDKN2A locus of chromosome 9 to be a
characteristic feature of anaplastic supratentorial ependymomas, and a reliable independent indicator of
unfavorable patient outcome (Korshunov et. Al. 2010). These findings supported earlier work by Taylor
et. Al. that identified CDKN2A deletion to be characteristic of supratentorial, but not posterior fossa nor
spinal ependymomas (Taylor et. Al. 2005).
In 2016, Pajtler, et. Al. assessed the DNA methylation profiles of ependymomas and suggested that
the three regional classifications of ependymoma neoplasms could be further classified into nine different
subgroups. Of the nine subgroups, one was characterized by a somatic gene rearrangement of RELA with
C11orf95 of chromosome 11. These ependymomas occurred exclusively in the supratentorial
compartment and predominantly in pediatric populations. They were further demonstrated to be the most
aggressive and lethal of all ependymomas, with poor clinical outcomes. Sanger sequencing of cDNA from
tumor samples by Pietsch et. Al. confirmed these findings and demonstrated that the novel fusion
transcript specifically consists of the N-terminal part of C11orf95 encoding 212aa of the 678aa
5

hypothetical protein sequence (exons 1 and 2) fusing to RelA. Only the first three amino acids of RelA
are deleted in-frame; the C-terminal RelA part of the putative fusion protein was found to contain almost
the full RelA sequence.
Treatment of Ependymoma
Currently, the primary treatment for ependymoma remains to be surgical resection followed by
radiotherapy. Although postoperative radiotherapy may induce stabilization and, occasionally, regression
of residual disease, chemotherapy is ineffective in most adult and pediatric patients (Yao et. Al. 2011,
Wu, Albertson, and Gilbert 2016). As a result, surgery and irradiation remain the mainstay for treatment
of ependymoma, and the tumors are incurable in up to 40% of cases. In general, the survival rate is
highest for those aged 20 – 44 years and decreases with increasing age at diagnosis. Even so, the 10-year
survival rate is 66% in children and adolescents aged 0 – 19 years and only 28.1% in those over the age of
75 (Wu, Albertson, and Gilbert, 2016). Seeing as no chemotherapy regimen has prolonged overall
survival in children or adults with ependymoma, and survival rates remain low, development of new
therapeutic options is needed to increase survival and reduce long-term sequels of current treatments.
With C11orf95-RELA fusion-positive ependymomas comprising the most lethal and aggressive of all
ependyomas, a greater understanding of the pathogenesis of this ependymoma subgroup is needed for
therapeutic development.
Cell of Origin of Ependymoma
In the hunt for more effective treatments for ependymoma, identification of the progenitor cell type
that gives rise to the neoplasms is one of the prevailing questions in the ependymoma field. Since the
discovery of cancer stem cells (CSC) in 2006 (Clarke and Fuller, 2006), the idea that a single multipotent
and self-renewing stem cell-like cell gives rise to all the phenotypically diverse cells of a tumor has
provided cancer researchers a practical focus point for studying the developmental and molecular events
of tumorigenesis (Poppleton and Gilbertson, 2007). In order to understand the search for CSC – like cells
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in ependymoma, it is important to understand the processes that regulate neurogenesis and the generation
of different glial and neural cell types in the CNS.
In vertebrates, neural stem cells first appear as a layer of pseudostratified epithelium that lines the
neural plate and neural tube before the onset of neurogenesis. These neuroepithelial cells (NECs) are
highly polarized cells – an important feature the contributes to the fate of daughter cells after mitosis. As
neurogenesis begins in the early days of embryonic development (E10 in mice), NECs give rise to radial
glial cells (RGCs), which retain the polarized features of NEC. These RGCs are mitotically active,
multipotent progenitor cells that possess the capacity for both symmetric and asymmetric division. When
RGCs divide symmetrically, they divide to generate two identical daughter cells that resemble the parent
radial glial cell, thus expanding he progenitor cell pool. In contrast, when RGCs divide asymmetrically,
they generate two different daughter cells: one stem cell (derived from the basal surface of the RGC), and
one cell that is fated to differentiate (generated from the apical surface of the RGC). These differentiating
cells ultimately give rise to the majority of neurons, oligodendrocytes, astrocytes, and ependymal cells of
the brain (Spassky et. Al. 2005). Development of the cerebral cortex is both spatially and temporally
controlled by RGC divisions. In mice, symmetric divisions of RGCs dominate leading up to E11. The
onset of neurogenesis occurs between E11 and E13, during which RGCs begin to divide asymmetrically.
After E17, gliogenesis begins and migrating cells complete differentiation into astrocytes,
oligodendrocytes, ependymal cells, and other glial cell types (Dwyer et. Al. 2016).
In normal tissues, stem cell self-renewal is tightly controlled. Deregulation of RGC division may thus
play a key role in the development of ependymoma. Indeed, over the last fifteen years, several studies
have generated support indicating that the cellular origin of ependymoma consists of an incompletely
defined population of neural stem cells, including radial glial cells (Morest and Silver, 2003; Taylor et.
Al. 2005).
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The Oncogenic C11orf95-RELA Fusion in Supratentorial Ependymoma
Studies of the progenitor cell type(s) that drive(s) tumorigenesis in ependymoma are largely
oversimplified unless coupled with an understanding of subtype differences among ependymoma tumors.
As discussed previously, supratentorial ependymomas are now known to be widely characterized by an
oncogenic fusion mutation between C11orf95 and RELA. Knowledge of the physiological functions of the
components in this oncogenic driver fusion mutation differ widely. The physiological function of
C11orf95 is unclear. C11orf95 has previously been described as a fusion partner of the gene coding the
transcription factor Mk12 in benign chondroid lipomas (Flucke et. Al. 2013). Sequence analysis indicates
the presence of two putative zinc finger domains, suggesting a role for C1orf95 in transcriptional
regulation.
While the physiological function of C11orf95 is largely unknown, that of RELA is well characterized.
RELA encodes RelA, a 65-kDa protein that interacts with IκB and p50 in the central signaling complex of
the NF-κB pathway. In the canonical NF-κB pathway, the NF-κB dimer is sequestered in the cytosol by
its inhibitor IκB (inhibitor of NF-κB) protein. Upon activation of cell surface receptors such as Toll-like
receptors and TNF cytokine receptors, a series of events occur proximal to the membrane, leading to the
activation of IKK (IκB kinase). Phosphorylation of IκBs via IKK results in their proteasomal degradation,
thus releasing NF-κB to translocate to the nucleus and activate gene transcription of target genes
(Napetschnig & Wu, 2013).
The main physiological function of NF-κB signaling is to orchestrate inflammatory responses to both
infection and tissue damage. It has also been shown to control cell proliferation and apoptosis. Not
surprisingly, it is frequently found to be involved in the pathogenesis of neoplasms – especially solid
tumors characterized by chronic inflammation. In addition to its implications in controlling inflammation,
proliferation, and apoptosis, NF-κB signaling can further contribute to tumorigenesis by controlling
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vascularization via upregulation of vascular endothelial growth factor (VEGF) and its receptor (Xie et. Al.
2010).
NF-kB Signaling in Supratentorial Ependymoma
While aberrant NF-κB signaling is a well-established driver of solid tumors, and mutations in NF-κB
genes such as RELA have been detected as genetic drivers of various malignancies (Courtois et. Al.
2006), significant genetic evidence of pathway involvement in supratentorial ependymoma (hereafter, STEPN) is lacking. In 2014, Pietsch et. Al. and Parker et. Al. simultaneously published findings
demonstrating that ST-EPNs carrying C11orf95-RELA fusions lead to pathological activation of the NFκB signaling pathway (Pietsch et. Al. 2014, Parker et. Al. 2014). In the latter study, RNA-seq gene
expression profiling demonstrated high levels of CCND1 and L1CAM expression in C11orf95-RELA
translocation-positive ependymomas. As CCND1 serves as a direct transcriptional target of NF-κB
signaling and L1CAM is associated with aberrant cell-cell adhesion and NF- κB activation in tumors,
these results suggest a role for atypical NF- κB signaling in ST-EPN. The group also demonstrated
aberrant NF- κB signaling in mouse neural stem cells (NSCs) – progenitor cells that are believed to be the
cells-of-origin of ependymoma. Transduction of the C11orf95-RELA fusion resulted in significant
activation of NF- κB target genes relative to NSCs transduced with C11orf95 or RELA alone. To couple
such findings with physiological effects in vivo, Parker et. Al. transduced isolated NSCs from transgenic
mice with either C11orf95RFP, RELARFP, or C11orf95-RELARFP retroviruses. NSCs transduced with each
virus were implanted into the cerebrum of 6-week old CD1-nude mice. While mice implanted with
C11orf95RFP or RELARFP viruses formed very few or no brain tumors, all mice implanted with the
C11orf95-RELARFP virus succumbed to brain tumors within 21 days. Brain tumors recapitulated
histological findings characteristic of human ST-EPN, and demonstrated similar immunoreactivity for
ST-EPN markers. In comparison to tumors of a separate mouse model of ST-EPN driven by EPHB2,
which is not specific to C11orf95-RELA positive ST-EPN, this C11orf95-RELA mouse tumor model
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exhibited marked upregulation of NF- κB genes, as shown by Ingenuity Pathway Analysis (IPA) (Parker
et. Al. 2014).
While Parker et. Al. demonstrated transformation of mouse embryonic NSCs and activation of NFκB by the C11orf95-RELA fusion ex vivo, in 2018 Ozawa et. Al. created a de novo mouse model
demonstrating tumor formation and NF- κB activation in vivo. Their mouse model utilized the RCAS/tv-a
system, a system previously developed for glia-specific gene transfer in transgenic mice. Gene set
enrichment analysis (GSEA) performed by Pietsch et. Al. further support evidence for a role of aberrant
NF- κB in ST-EPN tumorigenesis. In comparison to fusion-negative human ST-EPN cases, fusion
positive cases exhibited significant activation of NF- κB and interferon signaling, thus demonstrating
upregulation of NF- κB in human tumors.
Targeting NF-κB Subunits in Supratentorial Ependymoma
Although there is widespread evidence of NF- κB upregulation in C11orf95-RELA fusion ST-EPN
tumors, the contribution made by the NF- κB dimer in aberrant NF- κB signaling has not been
investigated. In vertebrates, NF- κB denotes not a single protein but a family of five transcription factors:
RelA/p65, c-Rel, RelB, p52, and p50, encoded by the rela, rel, relb, nfkb2, and nfkb1 genes, respectively.
These transcription factors combine as homo- or heterodimers to form 15 different possible NF- κB
protein dimers. All five NF- κB transcription factors share an N-terminal Rel homology domain (RHD),
responsible for DNA binding, nuclear localization, and homo- and heterodimerization. In contrast, the
transcriptional activation domain (TAD), which is needed for positive regulation of gene expression, is
present only in RelA, c-Rel, and RelB. As they lack TADs, p50 and p52 can repress transcription when
associated as homodimers or p50/p52 heterodimers. However, if associated with a TAD-containing NFκB family member or another protein capable of coactivator recruitment, this transcriptional repression
can be overridden. In addition to regulation via the presence or absence of a TAD, different NF- κB dimer
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combinations have differential sequence recognition specificities and affinities for different IκB proteins,
thus creating widespread variability in NF-κB signaling (Hoffman et. Al. 2006).
While support for upregulation of NF- κB signaling in ST-EPN is well documented, specifications
regarding the contributions and necessities of different NF- κB subunits in driving ST-EPN tumorigenesis
has not been investigated. To date, all gene expression profiling of NF- κB expression in ST-EPN has
been performed using tissue from ST-EPN tumors, neglecting consideration of cell heterogeneity within
the tumor. As discussed, NF- κB signaling plays a predominant role in regulation of inflammatory
processes. Thus, it is unknown whether upregulation of NF- κB signaling identified in the above studies is
occurring in non-oncogenic, neuroinflamatory cell populations or whether NF- κB signaling is
upregulated in the oncogenic, C11orf95-RELA expressing cell population to drive tumorigenesis. With
the NF- κB dimer serving as the central mediator of transcriptional regulation in the NF- κB signaling
pathway, we sought to investigate the implications of the different NF- κB transcription factors within the
oncogenic ST-EPN cell population in driving tumorigenesis.
Prior Models Utilized to Study Supratentorial Ependymoma
Development of supratentorial ependymoma is a highly complex process driven by a somatic gene
mutation occurring in an undefined population of progenitor cells in the cerebral cortex. In order to assess
if and how different NF- κB transcription factors contribute to ST-EPN tumorigenesis, a valid model that
enables cell-specific and temporal control is thus required. Models of ST-EPN have progressed
significantly since 2000. In 2005, Taylor et. Al. performed a combination of oligonucleotide gene
expression arrays and array comparative genomic hybridization (aCGH) to show that supratentorial,
posterior fossa, and spinal ependymomas possess different gene expression signatures. The differential
gene expression signatures included genes regulating neural precursor cell proliferation and
differentiation in the corresponding tumor region of the CNS. Specifically, supratentorial tumors
expressed markedly elevated levels of members of the NOTCH and EPHB-EPHRIN cell signal systems,
11

which normally act to maintain normal neural stem cells in the cerebral SVZ. Interference with normal
EphB-Ephrin interactions in SVZ cells of mice disrupts neuroblast chain migration and dramatically
increases astrocyte proliferation, resulting in the formation of proliferative growths along the ventricle
surface (Conover et. Al. 2000). Data from such gene expression profiles has been used to generate cell
and animal models of ST-EPN.
In conjunction with their 2005 work, Taylor et. Al. generated a mouse model of posterior fossa
ependymoma (PF-EPN) using stereotactic injections of sorted tumor cell populations. Using
immunoglobulin-conjugated magnetic beads, the lab isolated cells from whole-cell populations of fresh
ependymoma samples that expressed gene markers for PF-EPN. Cells were injected into the superficial
cerebral cortex of 7-week-old NOD-SCID mice. Animals developed brain tumors with characteristic
morphological features of ependymoma. Xenografts from the tumors further recapitulated site-specific
gene expression signatures characteristic of the parent PF-EPN tumor (Taylor et. Al 2005).
In 2010, Johnson et. Al. developed the first mouse model of ST-EPN by amplification of EPHB2 in
mouse forebrain neural stem cells. Analysis of DNA copy number alterations, messenger mRNA, and
micro miRNA expression profiles among tumor samples segregated tumors by CNS location and
identified copy number variants and alterations that might contribute to disease and clonal selection in
different ependymoma subtypes. The Ink4a/Arf locus was found to be frequently deleted in human
cerebral ependymomas, and EPHB2 was identified as a common DNA copy number alteration - as
validated by prior studies (Taylor et. Al. 2005, Poppleton and Gilbertson 2007). To develop their model,
the lab isolated enhanced green fluorescent protein (eGFP)+ cells from the cerebrum of Ink4a/Arf+/+ and
Ink4a/Arf-/- embryonic day 14.5 mice, and cultured the cells under conditions to promote stem cell
growth. The group then challenged Ink4a/Arf-/- cells with Ephb2. Cultured cells were then implanted into
the cerebrum of immunocompromised mice. Over 50% of mice implanted with Ephb2 transduced
embryonic cerebral Ink4a/Arf-/- developed brain tumors within 200 days of implantation. These tumors
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were histologically similar to human ependymoma and demonstrated ultrastructural features characteristic
of human ependymoma, thus establishing the first mouse model of ST-EPN (Johnson et. Al. 2010).
After identification of the C11orf95-RELA fusion in ST-EPN, Parker et. Al. furthered the Johnson
mouse model using retroviruses. The group isolated NSCs from Ink4a/Arf-/-and Blbp-eGFP transgenic
mice and transduced them with a C11orf95-RELA retrovirus. NSCs transduced with the virus were then
implanted into the cerebrum of female 6-week old CD1-nude mice and analyzed for tumor development.
All mice implanted with NSCs containing the fusion construct developed brain tumors within 20 days.
These neoplasms recapitulated histological and morphological features of ST-EPN, and expressed
markers characteristic of supratentorial ependymoma (Parker et. Al. 2014).
While these models demonstrated that the C11orf95-RELA fusion can transform embryonic mouse
neural stem cells ex vivo, until 2018, whether the fusion could drive ependymomagenesis de novo in the
brain was publically unknown. In 2018, the Gilbertson lab developed a de novo mouse model using the
RCAS/TVA system to deliver the C11orf95-RELA fusion into specific brain cell types in the mouse
brain. Over 90% of mice injected with the fusion developed tumors within 2 months of injection. These
C11orf95-RELA induced tumors displayed histological and morphological features characteristic of
ependymoma, and electron microscopy and immunostaining identified several expression features
common to human ependymomas (Ozawa et. Al. 2018).
Although this de novo mouse model demonstrated transformation of embryonic neural mouse stem
cells to produce ST-EPN tumors, its ability to be utilized for additional studies of ST-EPN is limited.
While the RCAS/TVA system is a versatile tool for performing lineage tracing and gene function analysis
in vivo, the insert capacity of the virus is limited and its infection rate in vivo is relatively inefficient. The
insert size in RCAS systems is limited to 2.8 kB, thus limiting the genes that can be evaluated with this
system and excluding the ability to study key oncogenic factors involved in human cancers. In addition,
studies utilizing the RCAS system in various tissues have shown that the number of cells of the targeted
tissue that become infected in vivo is significantly limited. This low infection rate means that only very
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potent oncogenes are likely to stimulate tumor formation in vivo, thus limiting the specific candidate
genes that can effectively be studied in specific tissues (Ahronian and Lewis, 2017).
A De Novo Mouse Model of Supratentorial Ependymoma
To circumvent these drawbacks, our lab developed a de novo mouse model of ST-EPN using the
piggyBac transposase system coupled with in utero electroporation (IUE). The piggyBac transposase
system has been utilized as a lineage labeling system in various tissues (Kim et. Al. 2011, Ding et. Al.
2005, Saridey et. Al 2009, Yusa et. Al. 2009). In utero electroporation (IUE) has been utilized as an
efficient method to deliver multiple transgenes into murine neural progenitors in the developing forebrain,
and in studies of neocortical development (LoTurco et. Al. 2009). In 2012, Chen and LoTurco combined
a binary piggyBac transposon plasmid system with IUE to successfully develop a lineage and fatemapping tool for neural progenitors (Chen and LoTurco, 2012). In addition, the CRISPR/Cas9 system can
be used in combination with piggyBac transposase lineage labeling and IUE to induce somatic mutations
in cells in neural progenitor lineages and to investigate the effects on cells in each lineage (Chen et. Al.
2015). Here, we have utilized these methods to generate a mouse model of ST-EPN that circumvents the
limitations of the RCAS-TVA system.
The piggyBac transposase system has emerged as a promising non-viral vector system for efficient,
sustained and high level transgene expression in mammalian cells (Di Matteo et. Al 2012, Ding et. Al.
2005, Saridey, Liu, and Doherty 2009). Transposons are mobile genetic elements that can be utilized to
integrate transgenes into host cell genomes. The piggyBac transposon, originally isolated from the
cabbage looper moth, Trichoplusiani, is recognized as one of the most efficient DNA transposons for the
manipulation of mammalian genomes. The piggyBac tranposase system consists of two main
components: a donor plasmid and a helper plasmid. The donor plasmid carries the gene of interest,
flanked by two terminal repeat domains. The helper plasmid catalyzes the movement of the transposon
(gene of interest) via the expression of its piggyBac transposase (PBase) (Saridey, Liu, and Doherty
2009). By placing PBase activity under the direction of cell-type specific promoters, this system can be
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utilized to insert desired transposon(s) into specific cell populations. The system can be utilized with more
than one donor plasmid. In this way, fluorescent constructs such as GFP and mRFP can be used in
addition to other transgenes to enable lineage tracing.
ST-EPN is driven by a somatic gene mutation occurring in an undefined population of progenitor
cells in the cerebral cortex. Thus, an accurate model of ST-EPN requires cellular and temporal control of
transgene expression. In utero electroporation has emerged as an efficient method to deliver transgenes to
specific populations of cerebral cortical precursor cells at select developmental time points (LoTurco,
Manent, and Sidiqi 2009). In utero electroporation is ultimately a surgical operation whereby a pregnant
mouse (embryonic day [E]9 -16) is subjected to abdominal incision for access to and exposure of all its
uterine horns. Using pulled glass capillaries, desired transgenes are injected into a lateral ventricle of each
embryo. After injection of the DNA solution, each brain is individually electroporated via placement
between two electrode paddles on opposing hemispheres. Upon application of current pulses, transient
electropores are formed within cell membranes, allowing the uptake of large molecules such as DNA into
the cytoplasm (Shimogori and Ogawa, 2008). The electrode paddles have opposing charges. Application
of electroporation fields moves negatively charged DNA towards the positive electrode, therefore
enabling spatially directed cell transfection.
Thus, by combining the piggyBac transposase system with in utero electroporation, transgenes can be
delivered to specific cerebral cortical precursor cell populations at specific developmental time points.
The CRISPR/Cas9 system can layered into this system to enable time- and population-specific genome
editing. The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system, originally
identified as a mediator in adaptive immunity in bacteria and archaea, has become a powerful tool for
genome engineering over the last decade. The system utilizes Cas9, an RNA-guided endonuclease that
recognizes protospacer-adjacent motif sequences (PAMs), and a guide RNA (gRNA), that is
complementary to the target locus. The guide RNA directs Cas9 to its specified target for specific gene
ablation, given that the target has a proximal PAM sequence. The CRISPR/Cas9 system has progressed
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significantly since its development, now enabling correction of genetic mutations in vivo, multiplex
genome editing, introduction of new transgenes, and far more (Chen & LoTurco, 2012; Cong et. Al.
2013).
Here, we have used the piggyBac transposase system and IUE to create a novel mouse model of
ST-EPN. This model recapitulates morphological and genetic profiling characteristics of human ST-EPN,
as demonstrated by histology and gene expression analysis. The cell-specific and temporal control
provided by the model allows for an assessment of how different NF- κB transcription factors contribute
to ST-EPN tumorigenesis by targeting NF- κB within the oncogenic ST-EPN cell population. Current
literature demonstrates a role of the NF- κB pathway in ST-EPN tumorigenesis. However, the specific
contribution of the different NF-κB transcription factors in driving tumorigenesis within the oncogenic
ST-EPN cell population has not been investigated. Seeing as the p50 NF- κB transcription factor lacks a
TAD domain, we hypothesize that overexpression of this gene will attenuate ST-EPN tumorigenesis by
preventing transcriptional activation of target genes involved in ST-EPN oncogenesis.

METHODS
Plasmid Construction
Plasmids were constructed for development of an ST-EPN mouse model. To make pPBCAGFUS1-HA, pPBCAG-RELA-HA, pPBCAG-p50-Flag, and pPBCAG mCherry, N-terminal HA-tagged
C11orf95-RELA fusion (termed FUS1), HA-tagged RELA, Flag-tagged p50, and mCherry sequences,
respectively, were amplified and replaced the eGFP cassette of a previously constructed pPBCAG-eGFP
construct. Replacement was achieved using the EcoRI and Not1 sites of the original plasmid. For
construction of pCAG-PBase, the PBase coding sequence was directly inserted downstream of the CAG
promoter, a gift from Fuyi Chen.
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Cell Culture Transfection
Hek293T cells were plated 24 hours prior to transfection in a 12-well plate (~ 150 – 200K
cells/well). Cells were transfected at 70 – 80% confluency with plasmids diluted to 1.0 µg/µL prior to
transfection. Upon starting the transfection protocol, media was aspirated and replaced with 1 mL of fresh
media. Transfection was accomplished using the Lipofectamine LTX w/PLUS Transfection protocol.
Cells were harvested at 37C overnight and harvested 24 hours post-transfection. To harvest, cells were
washed with 1X PBS and incubated with 4% PFA (4% paraformaldehyde/PBS) at room temperature for
20 minutes. Cells were washed 3X with 1x PBS and prepared for immunocytochemistry.
Immunocytochemistry
Fixed Hek293T cells were incubated with blocking buffer (7.5% goat serum, 0.1% Triton-X 100 in 1X
PBS) for 1 hour at room temperature. Cells were washed 3X with 1x PBS, and incubated with primary
antibody in antibody buffer (10% goat serum, 0.05% Triton-X 100 in 1x PBS) for 2 hours at room
temperature. The following primary antibodies were used: Mouse anti-HA (1:1000, Invitrogen), Rabbit
anti-V5 (1:1000, Invitrogen), and Mouse anti-Flag (1:1000; NE BioLabs). Following incubation, cells
were washed 3x with 1x PBS and incubated with secondary antibody for 2 hours at room temperature in
antibody buffer. The following secondary antibodies were utilized: Goat anti-Rabbit Alexa Fluor® Plus
647 (1:1000, Invitrogen), Goat anti-Mouse Alexa Fluor® Plus 488 (1:1000, Invitrogen). After incubation,
cells were rinsed 1x with 1x PBS and incubated with 4-6-diaminodino-2-phenylindole (1:2000, DAPI,
Invitrogen) for 20 minutes in antibody buffer at room temperature for nuclear staining. Cells were washed
3x with 1x PBS and coverslips were mounted on slides for imaging on a Leica TCS Sp8 Confocal
microscope.
Colocalization Analysis
Single cell high magnification images were acquired on a Leica TCS SP8 Confocal microscope at
63X. Nuclear regions were drawn free-hand to designate the region of interest for colocalization analysis
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via Coloc2 of the ImageJ imaging software, which was set to perform pixel intensity correlation over
space methods of Pearson. Threshold pixel intensity was set to minimum of 0 pixels. Pearson’s R values
of n = 6 cells were averaged to obtain assessments of protein colocalization.
Animals
CD1 mice were obtained from Charles River Laboratories, Inc. (Wilmington, MA), and
maintained at the University of Connecticut vivarium. Animal gestation ages were determined and
confirmed during surgery. Both male and female embryos were used for surgery, and all procedures and
experimental approaches were approved by the University of Connecticut IACUC.
In Utero Electroporation
In utero electroporation was performed as previously described [28, 29]. Briefly, mice were
anesthetized with a mixture of ketamine/xylazine (100/10 mg/kg i.p.). Metacam analgesic was
administered daily at dosage of 1 mg/kg sub cutaneously at 24 and 48 hours following surgery. To
visualize the plasmid during electroporation, plasmids were mixed with 2 mg/ml Fast Green (Sigma). In
all conditions described, pPBCAG-FUS1-HA, pPBCAG eGFP, pPBCAG mCherry, and the helper
plasmid CAG-PBase were used at the final concentration of 1.0 µg/µL. pPBCAG-RELA-HA, pPBCAGp50-Flag, and PX330-p50 were used at a final concentration of 1.5 µg/µL. Electroporation was performed
at embryonic day 12 or 14 (E12 or E14). During surgery, the uterine horns were exposed and one lateral
ventricle of each embryo was pressure injected with 1–2 µl of plasmid DNA. Injections were made
through the uterine wall and embryonic membranes by inserting a pulled glass microelectrode
(Drummond Scientific) into the lateral ventricle and injecting by pressure pulses delivered with a
Picospritzer II (General Valve). Electroporation was accomplished with a BTX 8300 pulse generator
(BTX Harvard Apparatus) and BTX tweezertrodes. A voltage of 65–75V was used for electroporation.
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Immunohistochemistry
Animals were deeply anesthetized with isoflurane and perfused transcardially with 4%
paraformaldehyde/PBS (4% PFA). Brain samples were post fixed for 24 hours in 4% PFA and sectioned
at 65µm thickness on a vibratome (Leica VT 1000S). Sections were processed as free-floating sections.
After blocking in PBS containing 5% normal goat serum (Sigma) and 0.3% Triton X-100 (Sigma) for 2
hours at room temperature, tissue sections were incubated with primary antibodies overnight at 4 ◦C in the
blocking solution. The following primary antibodies were used (separately): rabbit anti-HA (1:1000,
Invitrogen), and rabbit anti-V5 (1:1000, Invitrogen). Tissue sections were washed in PBS, incubated with
the appropriate secondary antibodies (Goat anti-Rabbit Alexa Fluor 647; 1:2000, Invitrogen), for 2 hours
at room temperature and washed in PBS. Nuclei were labeled 4-6-diaminodino-2-phenylindole (1:2000,
DAPI, Invitrogen). Whole brain and high magnification images were acquired on a Leica TCS SP8
confocal system.
Tumor Area Analysis
Transfected and/or tumor regions were imaged on a Leica TCS Sp8 confocal microscope and
processed using FIJI Imaging software. Tumor nodules were outlined free-hand to create a region of
interest for tumor area analysis. In brains containing more than one tumor nodule, nodules were assessed
separately and their measurements summed to obtain total area. Total of n = 6 brains were analyzed for
each condition.
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RESULTS
Upregulation of the NF- κB pathway in ST-EPN is well supported in the literature (Pietsch et. Al.
2014; Parker et. Al. 2014; Gilbertson et. Al. 2018). However, whether the ST-EPN C11orf95-RELA
fusion interacts with the different NF- κB transcription factor subunits in the oncogenic ST-EPN cell
population is unknown. This prompted us to investigate the biochemical interactions of C11orf95-RELA
with the five different NF-κB subunits: RelA, RelB, c-Rel, p50, and p52. Generation of p50 is
accomplished via endoproteolytic cleavage of the precursor, p105. Similarly, p52 is generated from its
precursor protein, p100. To account for the potential that the C11orf95-RELA fusion interacts with p50
and/or p52 prior to protein processing, we therefore also tested for the interaction of C11orf95-RELA
with p105 and p100. Hek293T cells were transfected with an HA-tagged fusion construct. Following
immunoprecipitation, blots were stained to detect each of the NF- κB subunits: RelB, c-Rel, p50, p52, the
p50 precursor p105, and the p52 precursor p100. All NF- κB subunits were detected in whole cell lysate
(WCE) and the C11orf95-RELA fusion co-immunoprecipitated with RelB, c-Rel, p50, and p105. We
also previously developed various fusion mutants containing mutations or deletions in various regions of
the C11orf95 domain. These mutants included a fusion with a mutation in the zinc finger domain of
C11orf95 (HA-FUS1-ZFD-∆AA) and a mutant comprised of the fusion with a deletion of one of the
nuclear localization sequences in C11orf95 (HA-FUS1-NLS-Del). Both mutants demonstrated interaction
with NF- κB subunits RelB, cRel, p50, and p105 (Figure 1). These results show that the C11orf95-RELA
fusion is capable of interacting with other NF κB subunits, thus supporting a potential role for aberrant
NF- κB signaling in driving ST-EPN tumorigenesis.
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Figure 1: NF-kβ Subunits Interact with C11orf95-RELA Fusion in vitro
Pull down of Hek293T cells transfected with an HA-tagged C11orf95-RELA fusion construct. All
NF- κB subunits were detected in whole cell lysate (WCE) and immunoprecipitated C11orf95-RELA
fusion stained positively for RelB, c-Rel, p50, p105, and p100. Fusion mutants containing a fusion
with a mutation in the zinc finger domain of C11orf95 (HA-FUS1-ZFD-∆AA) and a mutant
comprised of the fusion with a deletion of one of the nuclear localization sequences in C11orf95 (HAFUS1-NLS-Del) both demonstrated interaction with NF- κB subunits RelB, cRel, p50, p105, and
p100. Data provided in collaboration with Jianguo Wu.
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Next, we looked to see where the fusion and NF- κB proteins were localizing within cells. We
developed differentially tagged constructs – an HA-tagged C11orf95-RELA fusion plasmid, a V5-tagged
C11orf95-RELA fusion plasmid, an HA-tagged RELA plasmid, and a Flag-tagged p50 plasmid. Hek293T
cells were transfected with C11orf95-RELA-HA, RELA-HA, or p50-Flag constructs and imaged at high
magnification to assess the cytoplasmic vs. nuclear localization of each protein. All proteins localized to
cell nuclei, showing no positive staining in the cytoplasm (Supplemental Figure 1). To gain insight into
whether these constructs may be localizing to similar regions within the nucleus to influence gene
expression, we then sought to assess the degree of colocalization of the proteins within cell nuclei.
Hek293T cells were co-transfected with the following combinations: HA-tagged C11orf95-RELA and
V5-tagged C11orf95-RELA, V5-tagged C11orf95-RELA and HA-tagged RELA, or HA-tagged
C11orf95-RELA and Flag-tagged p50. Following immunostaining, single cell nuclei were imaged (Figure
2A) and the degree of colocalization was quantified using the Coloc2 add-on of the FIJI imaging
software. Analysis of pixel intensity colocalization demonstrated that the C11orf95-RELA fusion
demonstrates positive nuclear colocalization with itself, with an average Pearson’s R value of 0.837 ±
0.0564. Similarly, the C11orf95-RELA fusion demonstrates positive nuclear colocalization with RELA
(Avg. Pearson’s R Value = 0.745 ± 0.0957). In contrast, the C11orf95-RELA fusion demonstrated no
significant correlation in nuclear colocalization with p50 (Avg. Pearson’s R Value = -0.130 ± 0.3005)
(Figure 2B). These results suggest that the C11orf95-RELA fusion may be capable of homodimerization.
They also demonstrate that RelA and C11orf95-RELA have similar nuclear localization patterns,
suggesting that RelA and C11orf95-RELA may have similar DNA binding sites, and/or that the
C11orf95-RELA fusion is capable of heterodimerizing with RELA to influence gene expression. In
conjunction with our findings that C11orf95-RELA interacts with p50 (Figure 1), this data suggests that
while C11orf95-RELA interacts with p50, p50 also localizes to different nuclear locations independently
of dimerization with C11orf95-RELA.
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Figure 2: C11orf95-RELA Demonstrates Better Nuclear Colocalization with other C11orf95RELA Constructs and RelA than p50 in Hek293T Cells
(A) Representative images of nuclear colocalization in Hek293T cells co-transfected with: FUS1-V5
and FUS1-HA, FUS1-HA and p50, or FUS1-V5 and RELA-HA. Scale bar = 5 µm.
(B) Quantitative colocalization analysis of Hek293T cells transfected with: FUS1-V5 and FUS1-HA,
FUS1-HA and P50-Flag, or FUS1-V5 and RELA-HA (n = 6 cells in each transfection condition).
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Biochemical analysis demonstrated interaction of C11orf95-RELA with p50 and RELA. To
assess potential functional in vivo effects due to C11orf95-RELA interaction with NF- κB subunits RelA
and/or p50, we developed a de novo mouse model of ST-EPN, as previously described. Following in
utero electroporation at E12 – E14, all mice were harvested between P14 and P21 to assess for tumor
presence and size. Only brains demonstrating successful transfection (via GFP signal) were utilized for
analysis. Transfected brain slices were stained with 4-6-diaminodino-2-phenylindole to visualize tumor
nodules, and imaged on a Leica TCS Sp8 Confocal microscope (Figures 3A and 4A).
Images were processed using FIJI imaging software to quantify tumor area (n = 5 - 9 brains per
condition). Animals expressing the C11orf95-RELA fusion alone had an average tumor area of 3,320,253
± 2,128,305 µm2. Those with C11orf95-RELA and overexpression of p50 had an average tumor area of
3,974,786 ± 1,850,118 µm2, and those with C11orf95-RELA and knock-out of p50 had an average tumor
area of 798,169.4375 ± 442,096 µm2. In comparison to WT C11orf95-RELA-HA, tumor area was
unchanged in C11orf95-RELA-HA + P50-Flag animals but was significantly reduced in C11orf95RELA-HA + P50 CRISPR animals (Figure 3B). In fact, some C11orf95-RELA-HA + P50 CRISPR
animals failed to generate tumors at all. In contrast, animals with C11orf95-RELA and overexpression of
RELA had an average tumor area of 17,856,057 ± 5,097,949 µm2. Tumor area was significantly increased
in C11orf95+RELA-V5 + RELA-HA animals in comparison to control (Figure 4B). Animals expressing
P50 or P50 CRISPR without the C11orf95-RELA fusion failed to produce tumors, and were not included
in the tumor area analysis (Supplemental Figure 2).
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Figure 3: Knockdown of NF-κB Subunit p50 in Conjunction with WT C11orf95-RELA Fusion
Reduces Ependymoma Tumor Size
(A) Representative images of tumors generated from WT HA-tagged C11orf95-RELA fusion
transfected mice, HA- tagged C11orf95-RELA with overexpression of p50, and HA-tagged C11orf95RELA with CRISPR/Cas9 knockdown of p50 (top to bottom). All brains were harvested at P21. Scale
bar = 1000 µm.
(B) Quantification of tumor area in µm2. n = 6 brains in C1orf95-RELA-HA, n = 9 brains in
C11orf95-RELA-HA + p50-Flag, n = 5 brains in C11orf95-RELA + p50 CRISPR.
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Figure 4: Overexpression of NF-κB Subunit RelA in Conjunction with WT C11orf95-RELA
Fusion Increases Ependymoma Tumor Size
(A): Representative images of tumors generated from WT HA-tagged C11orf95-RELA fusion
transfected mice (top) and V5- tagged C11orf95-RELA with overexpression of RelA (bottom). All
brains were harvested at P21. Scale bar = 1000 µm.
(B) Quantification of tumor area in µm2. n = 6 brains in each condition.
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While average tumor area was unchanged in C11orf95-RELA-HA + p50-Flag animals, it was
clear that transfected cell morphology was significantly altered. We thus investigated the ability of our
various constructs to alter ST-EPN cell morphology. Images of P14 - 21 animals were taken on a Leica
TCS Sp8 Confocal microscope at 40X and 63X to gain insight into cell cluster and single cell
morphology. Qualitatively, C11orf95-RELA animals demonstrated characteristic well circumscribed
tumor boundaries with rounded, well defined cell morphology. This phenotype was reproduced in
C11orf95-RELA-V5 + RELA-HA animals. In contrast, C11orf95-RELA-HA + p50-Flag tumors
displayed string-like, not well-defined borders composed of filamentous cells with numerous processes
(Figure 5, Figure 6A). Animals expressing Flag-tagged p50 or p50 CRISPR without the C11orf95-RELA
fusion exhibited normal astrocyte and neuronal morphology (Supplemental Figure 3). Interestingly, while
C11orf95-RELA-HA + P50 CRISPR animals did not demonstrate development of tumors (Figure 3A, B,
Figure 5), transfected cells demonstrated cell morphology characteristics of both normal astrocytes and
those found in p50-overexpressing animals (Figure 6B).

27

Figure 5: Overexpression of p50 Alters Neoplasm Morphology
(A) The WT fusion mutation generates tumors with well-defined borders and nodular morphology. In
comparison, overexpression of p50, in conjunction with the WT C11orf95-RELA fusion, generates
neoplasms with poorly defined tumor boundaries and altered cell morphology. Knockdown of p50 via
CRISPR/Cas9, in conjunction with the WT C11orf95-RELA fusion, does not inhibit proliferation.
However, proliferative masses are smaller in size in comparison to age-matched controls and tumor
nodules are dominated by C11orf95-RELA fusion-expressing cells. Scale bar = 500µm.
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A
Figure 6: Overexpression of p50, but
not RelA, Alters Transfected Cell
Morphology of Tumors
(A) Overexpression of p50 in
conjunction with the C11orf95-RELA
fusion generates transfected cells that are
morphologically distinct from WT
C11orf95-RELA. In contrast to the welldefined, rounded morphology of WT
transformed cells, transformed cells
generated from p50 overexpression have
extensive filamentous processes (arrow
heads). Overexpression of RELA with
the WT C11orf95-RELA fusion
generates transformed cells with similar
well-circumscribed cell borders and
minimal cell processes.
(B) C11orf95-RELA-HA + P50
transfected cells demonstrated cell
morphology characteristics of both
normal astrocytes and those found in
p50-overexpressing animals (arrow
heads).
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DISCUSSION
The composition of the NF- κB dimer influences its ability to recognize different DNA target
sequences. Each dimer combination has varying sequence recognition specificities. Thus, transcriptional
specificity is influenced by NF- κB dimer structure. The implications of this are supported in an
assessment of our colocalization studies. C11orf95-RELA did not colocalize with p50 as well as it did
with RELA or other C11orf95-RELA constructs. Endogenous p50-RELA or p50-p50 dimers may localize
to different locations within the genome than when in association with the C11orf95-RELA fusion as
Fusion-p50 dimers. In contrast, there was significant colocalization with RelA and C11orf95-RELA. This
could be a result of endogenous RelA binding to similar genomic targets as the C11orf95-RELA fusion,
and not necessarily due to Fusion-RelA interaction. This possibility is supported by the fact that the
C11orf95-RELA fusion has the same TAD domain as does endogenous RelA. In comparison, p50
entirely lacks a TAD domain, which may play a role in generating the differential genomic target
sequences. This suggests that our colocalization results may be explained by genomic interactions of p50
and RelA with their target sites in addition to effects of molecular interactions with C11orf95-RELA.
It is interesting to note that while C11orf95-RELA-HA + p50 CRISPR animals demonstrated a
reduction in tumor size, cells exhibited altered morphology similar to that found in C11orf95-RELA-HA
+ p50-Flag animals. Various interpretations for these seemingly conflicting findings are possible. It is
possible that cells with altered morphology comprise a lineage derived from a cell that failed to take up
the p50 CRISPR construct during transfection. It is also possible that the cells expressing altered
morphology are slowly growing tumor-like cells that will never form tumors (i.e. tumors stunted in
growth). Testing the former hypothesis would require further work utilizing a p50 antibody to determine
whether p50 is expressed in altered cells. Testing of the later could be performed with a developmental
time course to assess tumor development over time.
The in vitro results of this study demonstrate that there is an interaction between the NF-κB
subunits p50 and RelA with the ST-EPN fusion C11orf95-RELA. The in vivo results demonstrate that
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these interactions have functional consequences on ST-EPN tumor development and cell morphology.
How p50 and/or RelA over-and underexpression impact NF-κB dimerization at the cellular level can be
utilized to summarize the functional effects identified in this study (Figure 7).
Overexpression of RELA generates larger ST-EPN tumors, while overexpression of p50 creates
tumors with altered cell morphology. In contrast, knockdown of p50 reduces tumor size. In C11orf95RELA animals alone, the oncogenic cell population can be hypothesized to comprise a mixture of FusionFusion, Fusion-p50, and Fusion-RELA dimers. In C11orf95-RELA-HA + p50-Flag cells, there may be an
increased proportion of Fusion-p50 and p50-p50 dimers, while C11orf95-RELA-V5 + RELA-HA cells
may possess a greater proportion of Fusion-RELA and RELA-RELA dimers. In cells expressing
C11orf95-RELA-HA with a CRISPR knockdown of p50, there may be few Fusion-p50 dimers and a
greater proportion of Fusion-Fusion dimers. This suggests that RELA-Fusion and p50-Fusion dimers are
necessary for tumor formation, and that Fusion-Fusion dimers may not have high oncogenic capacity.
Further studies investigating the functional effects of RelA knockdown are needed assess the
oncogenic capacity of RelA in driving ST-EPN. To gain further insight into the mechanisms of ST-EPN
tumorigenesis, identification of the transcriptional targets of the C11orf95-RELA fusion are needed. If
and how these targets change with overexpression or knockdown of p50 or RelA would be useful in
gaining further insight into the functional results identified in these studies, and would greatly aid in our
understanding of ST-EPN tumorigenesis.
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Figure 7: Schematic Representation Demonstrating Potential Effects of RelA and p50
Manipulation on NF-κB Dimerization and ST-EPN Phenotype
In comparison to WT C11orf95-RELA, overexpression of p50 may create a larger proportion of p50Fusion and p50-p50 dimers, while knockdown of p50 reduces formation of such dimers, leading to a
greater proportion of fusion-fusion dimers. Similarly, overexpression of RelA along with C11orf95RELA may lead to a greater proportion of RelA-Fusion dimers. Coupled with the phenotypic results
identified in this study, this suggests that Fusion-p50 and/or Fusion-RelA dimers are necessary for
tumor formation, and that Fusion-Fusion dimers may not have high oncogenic capacity.
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Supplemental Figure 1. The C11orf95-RELA Fusion and NF-κB Subunits p50 and RelA
Localize to Nuclei in Hek293T Cells

Scale bar = 5µm.
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Supplemental Figure 2: Overexpression or Knockdown of p50 Alone does not Generate Tumors
Representative images showing that overexpression or CRISPR/Cas9-mediated knockdown of p50
(without the C11orf95-RELA fusion) is insufficient to generate tumors. Scale bar = 500 µm.
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Supplemental Figure 3: Overexpression or Knockdown of p50 Alone does not Generate Altered
Transfected Cell Morphology
Representative images showing that overexpression or CRISPR/Cas9-mediated knockdown of p50
(without the C11orf95-RELA fusion) does not generate the aberrant transfected cell morphology seen
in C11orf95-RELA + p50-Flag animals. Transfected cells demonstrate normal neuronal and astrocyte
morphology.
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